SG Americas Securities LLC Grows Stock Position in Replimune Group, Inc. $REPL

SG Americas Securities LLC lifted its stake in Replimune Group, Inc. (NASDAQ:REPL) by 110.8% during the 1st quarter, Holdings Channel reports. The institutional investor owned 151,674 shares of the company’s stock after buying an additional 79,719 shares during the period. SG Americas Securities LLC’s holdings in Replimune Group were worth $1,160,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently modified their holdings of the stock. International Assets Investment Management LLC bought a new position in Replimune Group during the 4th quarter worth approximately $29,000. Russell Investments Group Ltd. lifted its position in Replimune Group by 3,638.9% in the third quarter. Russell Investments Group Ltd. now owns 7,777 shares of the company’s stock valued at $33,000 after purchasing an additional 7,569 shares during the last quarter. CWM LLC boosted its stake in shares of Replimune Group by 248.6% during the fourth quarter. CWM LLC now owns 4,047 shares of the company’s stock valued at $39,000 after purchasing an additional 2,886 shares during the period. BNP Paribas Financial Markets boosted its stake in shares of Replimune Group by 99.8% during the third quarter. BNP Paribas Financial Markets now owns 13,762 shares of the company’s stock valued at $58,000 after purchasing an additional 6,873 shares during the period. Finally, Raymond James Financial Inc. bought a new position in shares of Replimune Group in the second quarter worth approximately $69,000. Institutional investors own 92.53% of the company’s stock.

Replimune Group Stock Performance

Shares of REPL opened at $11.58 on Friday. The firm’s 50-day moving average price is $7.16 and its 200-day moving average price is $7.35. The firm has a market capitalization of $972.03 million, a price-to-earnings ratio of -3.43 and a beta of 0.86. The company has a current ratio of 5.60, a quick ratio of 5.60 and a debt-to-equity ratio of 0.33. Replimune Group, Inc. has a 1-year low of $1.50 and a 1-year high of $13.24.

Replimune Group (NASDAQ:REPL) last released its quarterly earnings results on Monday, June 29th. The company reported ($0.76) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.66) by ($0.10). Sell-side analysts anticipate that Replimune Group, Inc. will post -2.25 EPS for the current year.

Wall Street Analyst Weigh In

Several research analysts recently commented on the stock. BMO Capital Markets raised shares of Replimune Group from an “underperform” rating to an “outperform” rating and set a $16.00 target price on the stock in a research note on Tuesday, June 30th. Jefferies Financial Group reissued a “hold” rating and set a $2.00 price target (down from $13.00) on shares of Replimune Group in a research report on Monday, April 13th. Piper Sandler cut shares of Replimune Group from an “overweight” rating to a “neutral” rating and set a $4.00 price objective on the stock. in a research report on Friday, April 10th. Leerink Partners reaffirmed a “market perform” rating and set a $2.00 price objective (down from $11.00) on shares of Replimune Group in a research note on Monday, April 13th. Finally, JPMorgan Chase & Co. upgraded shares of Replimune Group from a “neutral” rating to an “overweight” rating and set a $17.00 target price for the company in a report on Friday, June 26th. Two equities research analysts have rated the stock with a Buy rating, six have given a Hold rating and two have issued a Sell rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus price target of $8.12.

Insider Buying and Selling at Replimune Group

In other Replimune Group news, insider Christopher Sarchi sold 12,000 shares of the company’s stock in a transaction that occurred on Monday, June 1st. The stock was sold at an average price of $9.24, for a total transaction of $110,880.00. Following the transaction, the insider owned 180,962 shares in the company, valued at approximately $1,672,088.88. This represents a 6.22% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Company insiders own 5.20% of the company’s stock.

About Replimune Group

Replimune Group, Inc is a clinical‐stage biotechnology company focused on developing next‐generation oncolytic immunotherapies for the treatment of solid tumors. The company’s proprietary “RP” platform leverages genetically engineered herpes simplex virus type 1 (HSV-1) vectors armed with immunomodulatory payloads to selectively infect, replicate within and destroy cancer cells, while also stimulating systemic antitumor immune responses.

Replimune’s lead candidate, RP1, incorporates GM-CSF and a fusogenic protein to enhance both direct oncolysis and immune activation.